Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LON D LYNN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1497898282
CMS profile
204601
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$770.34

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $697.99 3
Food and Beverage $72.35 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $697.99 3
Exact Sciences Corporation $72.35 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LON D LYNN

NPI 1497898282 · CMS profile ID 204601

Allopathic & Osteopathic Physicians / Family Medicine

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497898282?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497898282?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497898282?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LON D LYNN, NPI 1497898282, CMS profile ID 204601, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1497898282?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $770.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exact Sciences Corporation $72.3509/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026547131 CMS
Eli Lilly and Company $218.9103/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031763801 CMS
Eli Lilly and Company $212.4403/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031832537 CMS
Eli Lilly and Company $266.6403/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031906693 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,623.35 59
PY2020 $4,240.58 60
PY2021 $1,059.37 59
PY2022 $317.77 13
PY2023 $770.34 4
PY2024 $2,741.69 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,774,310.43 131
PY2024 Recipient $1,401.65 10
PY2024 Principal investigator $1,886,016.65 154
PY2023 Recipient $1,734.07 2
PY2023 Principal investigator $1,613,093.87 174
PY2022 Recipient $7,938.00 2
PY2022 Principal investigator $1,203,947.96 117
PY2021 Recipient $1,793.52 3
PY2021 Principal investigator $874,519.06 78
PY2020 Principal investigator $706,623.45 80
PY2019 Recipient $1,208.55 9
PY2019 Principal investigator $596,855.42 115

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

164 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,971.05 12/31/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) No dispute reported 06/30/2026 1155803048
Principal investigator 1 Averitas Pharma Inc. $2,059.20 12/18/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123349227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,533.28 12/18/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082450114
Principal investigator 1 AstraZeneca Pharmaceuticals LP $62,117.75 12/13/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1110839856
Principal investigator 1 Averitas Pharma Inc. $4,136.40 12/10/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123349183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,599.84 12/10/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082448100
Principal investigator 1 SANOFI US SERVICES INC. $630.00 12/09/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128722691
Principal investigator 1 ABBVIE INC. $1,383.20 12/04/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1100758385
Principal investigator 1 Averitas Pharma Inc. $3,663.00 12/03/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123349090
Principal investigator 1 SANOFI US SERVICES INC. $6,650.00 12/03/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128722693
Principal investigator 1 Averitas Pharma Inc. $2,302.20 11/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348977
Principal investigator 1 Averitas Pharma Inc. $3,821.00 11/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348980
Principal investigator 1 Averitas Pharma Inc. $3,098.25 11/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348984
Principal investigator 1 Averitas Pharma Inc. $324.00 11/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348987
Principal investigator 1 Averitas Pharma Inc. $972.00 11/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348991
Principal investigator 1 Averitas Pharma Inc. $135.00 11/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348995
Principal investigator 1 Averitas Pharma Inc. $2,565.00 11/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,682.50 11/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,457.00 11/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,466.25 11/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445908
Principal investigator 1 Averitas Pharma Inc. $5,558.40 11/19/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348973
Principal investigator 1 ABBVIE INC. $2,500.00 11/14/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1100755443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,507.13 11/12/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444270
Principal investigator 1 ABBVIE INC. $497.25 11/06/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1100752867
Principal investigator 1 Averitas Pharma Inc. $8,693.10 11/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348900
Principal investigator 1 Averitas Pharma Inc. $5,000.00 11/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348903
Principal investigator 1 Averitas Pharma Inc. $2,250.00 11/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348907
Principal investigator 1 Averitas Pharma Inc. $5,000.00 11/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348910
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,721.87 11/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082443720
Principal investigator 1 Averitas Pharma Inc. $2,223.00 10/30/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348790
Principal investigator 1 Averitas Pharma Inc. $2,000.00 10/30/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348794
Principal investigator 1 Averitas Pharma Inc. $2,250.00 10/30/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348798
Principal investigator 1 Averitas Pharma Inc. $1,500.00 10/30/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348802
Principal investigator 1 UCB SA $4,750.00 10/28/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1153202603
Principal investigator 1 SANOFI US SERVICES INC. $1,850.00 10/21/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128722687
Principal investigator 1 Averitas Pharma Inc. $3,353.40 10/15/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348763
Principal investigator 1 SANOFI US SERVICES INC. $5,500.00 10/15/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128722685
Principal investigator 1 Averitas Pharma Inc. $6,031.80 10/10/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348737
Principal investigator 1 Averitas Pharma Inc. $1,913.40 10/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348715
Principal investigator 1 Averitas Pharma Inc. $309.60 10/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348718
Principal investigator 1 Averitas Pharma Inc. $3,375.00 10/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348722
Principal investigator 1 Averitas Pharma Inc. $1,620.00 10/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348726
Principal investigator 1 Averitas Pharma Inc. $405.00 10/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348730
Principal investigator 1 Averitas Pharma Inc. $2,653.00 10/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348733
Principal investigator 1 ABBVIE INC. $3,700.00 09/27/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100744834
Principal investigator 1 Averitas Pharma Inc. $270.00 09/24/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348584
Principal investigator 1 Averitas Pharma Inc. $6,068.25 09/24/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348602
Principal investigator 1 Averitas Pharma Inc. $4,212.00 09/24/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348606
Principal investigator 1 Averitas Pharma Inc. $1,791.00 09/18/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348540
Principal investigator 1 SANOFI US SERVICES INC. $3,050.00 09/16/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128722675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,750.00 09/12/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082437646
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,050.00 09/12/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082437660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,500.00 09/12/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082437670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 09/12/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082437704
Principal investigator 1 Averitas Pharma Inc. $11,219.40 09/10/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348484
Principal investigator 1 ABBVIE INC. $3,557.25 09/04/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1100741112
Principal investigator 1 ABBVIE INC. $1,542.45 09/03/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1100739710
Principal investigator 1 ABBVIE INC. $3,220.25 09/03/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100739712
Principal investigator 1 Averitas Pharma Inc. $2,697.30 09/03/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348365
Principal investigator 1 Averitas Pharma Inc. $2,642.40 08/27/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348354
Principal investigator 1 Mylan Specialty L.P. $5,000.00 08/26/2024 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1141407614
Principal investigator 1 SANOFI US SERVICES INC. $4,500.00 08/26/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128722673
Principal investigator 1 Averitas Pharma Inc. $9,477.00 08/19/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348314
Principal investigator 1 Averitas Pharma Inc. $2,842.20 08/13/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348264
Principal investigator 1 Averitas Pharma Inc. $2,775.60 08/07/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348228
Principal investigator 1 SANOFI US SERVICES INC. $3,075.00 08/05/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128722667
Principal investigator 1 SANOFI US SERVICES INC. $4,800.00 08/05/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128722669
Principal investigator 1 Averitas Pharma Inc. $5,430.60 08/01/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348214
Principal investigator 1 Averitas Pharma Inc. $2,775.60 07/30/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348200
Principal investigator 1 SANOFI US SERVICES INC. $6,750.00 07/29/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128722663
Principal investigator 1 SANOFI US SERVICES INC. $1,850.00 07/29/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128722671
Recipient Regeneron Pharmaceuticals, Inc. $15.10 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082395658
Recipient Regeneron Pharmaceuticals, Inc. $15.10 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082395660
Recipient Regeneron Pharmaceuticals, Inc. $44.50 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082395662
Recipient Regeneron Pharmaceuticals, Inc. $60.40 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082395664
Recipient Regeneron Pharmaceuticals, Inc. $70.01 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082395666
Recipient Regeneron Pharmaceuticals, Inc. $233.63 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082395668
Recipient Regeneron Pharmaceuticals, Inc. $305.89 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082395670
Recipient Regeneron Pharmaceuticals, Inc. $32.57 07/25/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082395654
Recipient Regeneron Pharmaceuticals, Inc. $128.98 07/25/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082395656
Principal investigator 1 Averitas Pharma Inc. $8,534.70 07/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348163
Recipient Regeneron Pharmaceuticals, Inc. $495.47 07/15/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082395652
Principal investigator 1 Averitas Pharma Inc. $7,253.10 07/10/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348045
Principal investigator 1 ABBVIE INC. $1,856.25 07/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1100726802
Principal investigator 1 ABBVIE INC. $2,397.05 07/03/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100725322
Principal investigator 1 Averitas Pharma Inc. $2,940.30 07/02/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348041
Principal investigator 1 Averitas Pharma Inc. $2,059.20 06/25/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123348000
Principal investigator 1 Eli Lilly and Company $3,434.28 06/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1137355932
Principal investigator 1 Averitas Pharma Inc. $5,011.20 06/18/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347908
Principal investigator 1 Eli Lilly and Company $82,640.00 06/17/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1137357315
Principal investigator 1 Averitas Pharma Inc. $6,214.50 06/11/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347849
Principal investigator 1 Averitas Pharma Inc. $4,215.60 06/06/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347819
Principal investigator 1 ABBVIE INC. $1,542.45 06/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1100721598
Principal investigator 1 ABBVIE INC. $323.25 06/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100721682
Principal investigator 1 Averitas Pharma Inc. $309.60 05/28/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347793
Principal investigator 1 Averitas Pharma Inc. $2,004.75 05/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347702
Principal investigator 1 Averitas Pharma Inc. $2,430.00 05/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347706
Principal investigator 1 Averitas Pharma Inc. $1,080.00 05/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347709
Principal investigator 1 Averitas Pharma Inc. $101.25 05/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347713
Principal investigator 1 Averitas Pharma Inc. $1,603.80 05/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347717
Principal investigator 1 Averitas Pharma Inc. $11,475.00 05/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347720
Principal investigator 1 Averitas Pharma Inc. $8,529.30 05/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347724
Principal investigator 1 Averitas Pharma Inc. $476.00 05/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347727
Principal investigator 1 Averitas Pharma Inc. $928.80 05/14/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347597
Principal investigator 1 ABBVIE INC. $1,633.75 05/08/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100716514
Principal investigator 1 SANOFI US SERVICES INC. $1,100.00 05/06/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128722659
Principal investigator 1 SANOFI US SERVICES INC. $19,050.00 04/29/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128722657
Principal investigator 1 Averitas Pharma Inc. $309.60 04/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347504
Principal investigator 1 ABBVIE INC. $4,500.00 04/18/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1100714218
Principal investigator 1 ABBVIE INC. $1,486.90 04/18/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1100714460
Principal investigator 1 Averitas Pharma Inc. $309.60 04/16/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347457
Principal investigator 1 SANOFI US SERVICES INC. $1,495.00 04/15/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128722655
Principal investigator 1 Averitas Pharma Inc. $6,651.00 04/12/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347405
Principal investigator 1 ABBVIE INC. $3,267.50 04/04/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100712072
Principal investigator 1 Averitas Pharma Inc. $500.00 04/04/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347342
Principal investigator 1 Averitas Pharma Inc. $2,250.00 04/04/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347357
Principal investigator 1 ABBVIE INC. $7,241.40 03/28/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1100710078
Principal investigator 1 Averitas Pharma Inc. $2,337.30 03/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347302
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,800.00 03/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1110836836
Principal investigator 1 Biogen, Inc. $112,391.05 03/20/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) No dispute reported 06/30/2026 1104837320
Principal investigator 1 Eli Lilly and Company $558.94 03/20/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1137355798
Principal investigator 1 Eli Lilly and Company $5,635.00 03/19/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTERED WEEKLY USING A FIXED DOSE ESCALATION COMPARED TO INSULIN GLARGINE IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1137357313
Principal investigator 1 Mylan Specialty L.P. $14,643.76 03/19/2024 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1141407616
Principal investigator 1 ABBVIE INC. $2,500.00 03/12/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1100708171
Principal investigator 1 Averitas Pharma Inc. $6,511.50 03/12/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347238
Principal investigator 1 ABBVIE INC. $2,879.50 03/07/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100707338
Principal investigator 1 ABBVIE INC. $1,542.45 03/07/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1100707340
Principal investigator 1 ABBVIE INC. $12,500.00 03/07/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1100707342
Principal investigator 1 Averitas Pharma Inc. $1,414.80 03/07/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347190
Principal investigator 1 SANOFI US SERVICES INC. $8,550.00 03/04/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128722651
Principal investigator 1 AstraZeneca Pharmaceuticals LP $245,546.71 02/29/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomised Placebo-Controlled Double-Blind Multi-Centre 4-week 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide Glycopyrronium and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1110847705
Principal investigator 1 Averitas Pharma Inc. $3,261.60 02/29/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347153
Principal investigator 1 Averitas Pharma Inc. $12,447.90 02/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347047
Principal investigator 1 ABBVIE INC. $1,000.00 02/15/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1100703922
Principal investigator 1 Averitas Pharma Inc. $2,368.80 02/13/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347002
Principal investigator 1 Averitas Pharma Inc. $1,000.00 02/13/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347006
Principal investigator 1 Averitas Pharma Inc. $2,250.00 02/13/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347013
Principal investigator 1 Eli Lilly and Company $46,650.00 02/13/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137355796
Principal investigator 1 Eli Lilly and Company $4,965.00 02/12/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) No dispute reported 06/30/2026 1137355928
Principal investigator 1 Averitas Pharma Inc. $2,059.20 02/07/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123346970
Principal investigator 1 AstraZeneca Pharmaceuticals LP $39,198.63 01/31/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1110843598
Principal investigator 1 Averitas Pharma Inc. $552.60 01/31/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123346943
Principal investigator 1 Eli Lilly and Company $3,185.64 01/31/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1137356820
Principal investigator 1 SANOFI US SERVICES INC. $3,750.00 01/29/2024 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128722647
Principal investigator 1 AstraZeneca Pharmaceuticals LP $51,346.46 01/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) No dispute reported 06/30/2026 1110844916
Principal investigator 1 Averitas Pharma Inc. $2,775.60 01/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123346886
Principal investigator 1 Eli Lilly and Company $89,080.00 01/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1137355446
Principal investigator 1 Eli Lilly and Company $26,200.00 01/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1137356814
Principal investigator 1 ABBVIE INC. $4,045.00 01/17/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100700479
Principal investigator 1 Averitas Pharma Inc. $7,398.90 01/16/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123346824
Principal investigator 1 Eli Lilly and Company $2,700.00 01/16/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, TWO-ARM, PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1137357083
Principal investigator 1 ABBVIE INC. $1,802.50 01/10/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100699381
Principal investigator 1 ABBVIE INC. $1,880.45 01/10/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1100699505
Principal investigator 1 Averitas Pharma Inc. $15,333.30 01/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123346801
Principal investigator 1 Eli Lilly and Company $51,414.00 01/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1137355926
Principal investigator 1 Eli Lilly and Company $2,167.90 01/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137356818
Principal investigator 1 Averitas Pharma Inc. $850.00 01/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123346753
Principal investigator 1 Averitas Pharma Inc. $8,731.00 01/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123346761
Principal investigator 1 Averitas Pharma Inc. $5,184.00 01/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123346768
Principal investigator 1 Averitas Pharma Inc. $810.00 01/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123346772
Principal investigator 1 Averitas Pharma Inc. $2,700.00 01/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123346775
Principal investigator 1 Averitas Pharma Inc. $3,510.00 01/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123346779
Principal investigator 1 Averitas Pharma Inc. $309.60 01/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123346786
Principal investigator 1 Novartis Pharmaceuticals Corporation $490,547.26 01/01/2024 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1089687941